Skip to content

Author

Atsumi Ota

We have 2 of 7 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Enhanced NRF1-mediated proteasome bounce-back and nelfinavir-mediated bortezomib sensitization in gemcitabine/cisplatin-resistant bladder cancer cells.

Findings identify enhanced NRF1-mediated proteasome adaptation as a feature of GC resistance and highlight the need for highly selective DDI2 inhibitors to evaluate DDI2-NRF1 targeting as a strategy to improve PI efficacy in drug-resistant solid cancers.

Atsumi Ota, M. Kawai, Rin Himura et al. · 0 citations
Sep 2026

Upamostat potentiates bortezomib cytotoxicity and delays proteasome recovery in bortezomib-resistant malignant lymphoma cells through modulation of the DDI2/NRF1 axis.

Findings identify UMS as a candidate DDI2/NRF1-axis modulator that potentiates BTZ-induced cytotoxicity and delays functional proteasome recovery in BTZ-resistant malignant lymphoma cells.

Atsumi Ota, Sota Maruyama, Yudai Kudo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.